Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Veterinary Vaccines Market is predicted to reach US$ 13.09 billion by 2031 from US$ 7.65 billion in 2020, and to grow at a CAGR of ~5.0% between the forecast period 2021 to 2031.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2021 to 2031. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2020. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
Animal Type [Livestock Animals and Companion Animals], Vaccine Type [Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines and Recombinant Vaccines]
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Boehringer Ingelheim International GmbH, Intervet Inc., a subsidiary of Merck & Co. Inc., Zoetis, Elanco, Ceva, Virbac, Phibro Animal Health Corporation, Hester Biosciences Limited, HIPRA, Biogénesis Bagó, among others.
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2031
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Veterinary Vaccines - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Veterinary Vaccines - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Veterinary Vaccines - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Veterinary Vaccines - ANALYSIS & FORECAST, BY REGION
North America Veterinary Vaccines
1. North America Veterinary Vaccines , by Country
1. US
2. Canada
1. North America Veterinary Vaccines , by Product
2. North America Veterinary Vaccines , by Type
3. North America Veterinary Vaccines , by Gender
4. North America Veterinary Vaccines , by Sales Channel
3. Europe Veterinary Vaccines
1. Europe Veterinary Vaccines , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Veterinary Vaccines , by Product
3. Europe Veterinary Vaccines , by Type
4. Europe Veterinary Vaccines , by Gender
5. Europe Veterinary Vaccines , by Sales Channel
4. Asia Pacific Veterinary Vaccines
1. Asia Pacific Veterinary Vaccines , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Veterinary Vaccines , by product
3. Asia Pacific Veterinary Vaccines , by Type
4. Asia Pacific Veterinary Vaccines , by Gender
5. Asia Pacific Veterinary Vaccines , by Sales Channel
5. Rest of the World Veterinary Vaccines
1. Rest of the World Veterinary Vaccines , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Veterinary Vaccines , by Product
3. Rest of the World Veterinary Vaccines , by Type
4. Rest of the World Veterinary Vaccines , by Gender
5. Rest of the World Veterinary Vaccines , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 4